In yesterday’s Wall Street session, Merck & Co Inc (NYSE:MRK) shares traded at $106.23, up 1.11% from the previous session.
As of this writing, 28 analysts cover Merck & Co Inc (NYSE:MRK). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $135.00 and a low of $103.00, we find $125.00. Given the previous closing price of $105.06, this indicates a potential upside of 18.98 percent. MRK stock price is now 3.13% away from the 50-day moving average and -1.98% away from the 200-day moving average. The market capitalization of the company currently stands at $269.19B.
There are 6 analysts who have given it a hold rating, whereas 19 have given it a buy rating. Brokers who have rated the stock have averaged $124.78 as their price target over the next twelve months.
With the price target of $115, Deutsche Bank recently initiated with Buy rating for Merck & Co Inc (NYSE: MRK).
In other news, Oosthuizen Johannes Jacobus, President, U.S. Market sold 2,081 shares of the company’s stock on Nov 09. The stock was sold for $213,061 at an average price of $102.38. Upon completion of the transaction, the President, U.S. Market now directly owns 18,191 shares in the company, valued at $1.93 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 08, EVP&Pres, Merck Animal Heallth DeLuca Richard R. sold 43,823 shares of the business’s stock. A total of $4,602,668 was realized by selling the stock at an average price of $105.03. This leaves the insider owning 111,764 shares of the company worth $11.87 million. Insiders disposed of 768,565 shares of company stock worth roughly $81.64 million over the past 1 year. A total of 0.14% of the company’s stock is owned by insiders.
Tuesday morning saw Merck & Co Inc (NYSE: MRK) opened at $104.92. During the past 12 months, Merck & Co Inc has had a low of $99.14 and a high of $119.65. As of last week, the company has a debt-to-equity ratio of 0.85, a current ratio of 1.38, and a quick ratio of 1.12. According to the stock market information, the enterprise value for the company is $292.31B, which is based on a 59.01 price-to-earnings ratio, a 5.87 price-to-earnings-growth ratio, and a beta of 0.35. The fifty day moving average price for MRK is $103.00 and a two-hundred day moving average price translates $108.37 for the stock.
The latest earnings results from Merck & Co Inc (NYSE: MRK) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $2.13, beating analysts’ expectations of $1.95 by 0.18. This compares to $1.28 EPS in the same period last year. The net profit margin was 7.93% and return on equity was 10.75% for MRK. The company reported revenue of $15.96 billion for the quarter, compared to $14.96 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.7 percent. For the current quarter, analysts expect MRK to generate $14.51B in revenue.
Merck & Co Inc(MRK) Company Profile
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo’s DXd antibody drug conjugate (ADC) candidates. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
